Month: September 2026

Highlights

• Maiden 2,500m diamond drill program at Luanshya West scheduled to commence during the week of 21 September, with completion expected by end-of-year
• Drilling will test up to four priority targets, targeting vertical depths of 100-250m
• Further exploration underway at Mpongwe to refine existing and new targets, with approximately 3,000 soil samples planned to be collected by end of year
• Agreement to increase Koryx’ ownership from 51% to 80%, with no remaining contractual expenditure commitments to complete earn-in

LUXEMBOURG, Sept. 18, 2026 (GLOBE NEWSWIRE) — Koryx Copper S.A. (TSX:KRY.V) (NSX:KYX) (OTCQX:KRYXF)   (“Koryx” or the “Company”) is pleased to announce it has entered into an amended and restated option agreement (the “A&R Option Agreement”) with World Class Mineral Ventures Limited (“WCMV”). Pursuant to the A&R Option Agreement, Koryx, through its wholly owned subsidiary, Koryx Copper Mauritius, will increase its ownership interest in Koryx Copper Zambia Ltd (“KCZ”) from 51% to 80% (the “Transaction”). KCZ holds 100% of two large-scale exploration licenses at the Luanshya West Project (LEL 23246) and the Mpongwe Project (LEL 23248) located in the Zambian Copperbelt (the “Licenses”).

Heye Daun, Koryx Copper’s President & CEO commented: “While the Haib project in Namibia remains our primary focus, our Zambian exploration programs have made significant progress since Koryx’ management transition. Detailed magnetic surveying, soil sampling, and pitting at Luanshya West have helped identify and prioritise four targets which we will begin drilling this month, while regional sampling and our reassessment of exploration data at Mpongwe have confirmed new targets for infill sampling to be completed later this year.

We continue to be encouraged by the exploration progress and resource potential in Zambia and have therefore decided to accelerate our ownership in Koryx Copper Zambia Ltd which holds both Luanshya West and Mpongwe. This gives us greater flexibility to assess our strategic options to monetize the Zambian Projects, while continuing to retain our operational and financial emphasis on the advancement of Haib.”

Amended and Restated Option Agreement

The A&R Option Agreement amends and restates Koryx’ 2022 earn-in agreement with WCMV (the “Initial Agreement”). Under the Initial Agreement, Koryx could earn an interest of up to 80% in three large-scale exploration licenses held by WCMV (LEL 23246, LEL 23247 and LEL 23248, collectively, the “Initial Licenses”). Koryx had acquired a 51% interest in the Initial Licenses by way of earn-in. Increasing Koryx’ interest from 51% to 80% originally required a further US$3 million in exploration expenditure over three years, with approximately US$1.1 million spent to date, together with US$90,000 in cash and additional share payments. The Company had already relinquished LEL 23247, leaving Luanshya West and Mpongwe as the two projects covered by the amended agreement.

On closing, the A&R Option Agreement will increase Koryx’ interest in these two projects to an effective 80%, indirectly through its 80% ownership of KCZ, and eliminate the remaining contractual earn-in expenditure commitments. The aggregate consideration payable by Koryx at closing of the Transaction is: (a) US$200,000 in cash; and (b) 80,000 common shares in the capital of Koryx (the “Common Shares”) at a deemed price of C$3.50 per Common Share, subject to any adjustment required by the TSX Venture Exchange (the “Exchange”). The amended agreement also provides a conditional right for Koryx to acquire the remaining 20% interest for US$400,000 if WCMV elects not to contribute its share of future project funding.

The Transaction constitutes an “Expedited Acquisition” in accordance with Exchange policies. The Common Shares issuable under the A&R Option Agreement will be subject to a hold period of four months and one day pursuant to Canadian securities laws. Closing of the Transaction is subject to customary closing conditions, including acceptance by the Exchange, and is expected to occur no later than the outside date of September 30, 2026. No finder’s fees are payable.

Zambia Projects Exploration Update

The Company is pleased to provide an update on exploration activities in Zambia, where fieldwork has commenced on both the Luanshya West (license 23246-HQ-LEL) and Mpongwe (23248-HQ-LEL) projects.

At Luanshya West an initial diamond drill program will commence before the end of September 2026 aimed at testing three or four targets with 2,500m of drilling (see Figure 1 below). Drill holes will be inclined and test surface geochemistry anomalies, induced polarization (IP) chargeability and resistivity features and structural targets to a vertical depth of 100m to 250m. The drill program is expected to be completed by mid-December this year.

At the Mpongwe project, follow up and in-fill soil sampling will be completed on targets identified during 2025 sampling programs (at Lwabufubu, MP1 and MP2 targets), as well as completing regional soil sampling in the western parts of the license which could not be sampled in 2025. The sampling is expected to be completed in early November and will total about 3,000 samples. Results and possible early onset of the rainy season will determine whether follow up shallow drilling will be carried out in late 2026 or be delayed until 2027.

Figure 1: Luanshya West license with four targets to be drill tested (highlighted as black boxes)

Quality Assurance / Quality Control

All drill core is HQ sized at collar and reduced to NQ size in fresh rock. The core was all logged, photographed, and cut in half with a diamond saw. Half of the core was bagged and sent to ALS Laboratories Ltd. in Johannesburg, South Africa for analysis (SANAS Accredited Testing Laboratory, No. T0387) and ActLabs in Canada, while the other half was quartered with one quarter archived and stored on site for verification and reference purposes while the other quarter will be used for metallurgical test work. 33 elements are analyzed by Inductively Coupled Plasma (ICP) utilizing a 4-acid digestion and gold is assayed for using a 30g fire assay method. Duplicate samples, blanks, and certified standards are included with every batch and are actively used to ensure proper quality assurance and quality control (“QA/QC”) The QA/QC frequency is 1 in 20 for each of blanks, duplicates and standards. 

Qualified Persons

Mr. Dean Richards, BSc. (Hons) Geology, Pr.Sci.Nat., MGSSA – is the Qualified Person for the Haib Copper Project and has reviewed and approved the scientific and technical information in this news release and is a registered Professional Natural Scientist with the South African Council for Natural Scientific Professions (Pr.Sci.Nat. No. 400190/08). Mr. Richards is independent of the Company and its mineral properties and is a Qualified Person for the purposes of National Instrument 43-101.

About Koryx Copper S.A.

Koryx Copper S.A. is a Luxembourg domiciled copper development Company focused on advancing its 100% owned Haib Copper Project in Namibia whilst also building a portfolio of copper exploration licenses in Zambia. Haib is a large copper porphyry deposit in southern Namibia with significant gold and molybdenum credits and a long history of exploration and project development by multiple operators.

More than 155,000m of drilling has been conducted at Haib since the 1970’s with significant exploration programs led by companies including Falconbridge (1964), Rio Tinto (1975), Teck (2014) and Koryx Copper (2021-2026). Extensive further drilling, metallurgical testing and various technical studies have been completed at Haib. Additional studies are underway aiming to demonstrate Haib as a future long-life, low-cost, low-risk open pit, sulphide milling and flotation copper project with additional heap leach potential.

Mineralisation at Haib is typical of a porphyry copper deposit and is dominantly chalcopyrite with minor bornite and chalcocite present and only minor secondary copper minerals at surface due to the arid environment. Haib is one of only a few examples of a Paleoproterozoic porphyry copper deposit in the world. Due to its age, the deposit has been subjected to multiple metamorphic and deformation events but still retains many of the classic mineralisation and alteration features typical of these deposits.

Further details of the Haib Copper Project are available in the technical report titled “March 2026 Mineral Resource Estimate Haib Copper Project, Namibia, National Instrument 43-101 Technical Report” dated effective March 16, 2026. The report and other information are available on the Company’s website at www.koryxcopper.com and under the Company’s profile on SEDAR+ at www.sedarplus.ca.

Additional information is also available by contacting the Company:

Aideen McDermott
Investor Relations
amcdermott@koryxcopper.com
+1-416-837-7680

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Information

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the future or prospects of the Haib project or the Company, including prospective production rates and life-of-mine, the timing of publishing a PFS, the commencement of trading of the Shares under the new Company name, and the effective date of the new CUSIP and ISIN assigned to the Shares. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect “, “is expected “, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking statements are necessarily based upon a number of assumptions that, while considered reasonable by management, are inherently subject to business, market, and economic risks, uncertainties, and contingencies that may cause actual results, performance, or achievements to be materially different from those expressed or implied by forward-looking statements. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, other factors may cause results not to be as anticipated, estimated, or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Other factors which could materially affect such forward-looking information are described in the risk factors in the Company’s most recent annual management discussion and analysis. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a9aa54f1-a838-43b0-8d99-62c219081372

BEDFORD, Mass., Sept. 18, 2026 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it has granted inducement equity awards to nine newly hired non-executive employees. The awards were made as an inducement material to each recipient’s acceptance of employment with Ocular under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards were granted effective as of September 14, 2026, and consist of non-statutory stock option awards to purchase up to an aggregate of 64,850 shares of Ocular’s common stock and restricted stock unit awards representing the right to receive an aggregate of 21,350 shares of Ocular’s common stock. The stock option awards have an exercise price of $10.72 per share, equal to the closing price of Ocular’s common stock on The Nasdaq Global Market on the effective date of grant. Each of the stock option awards has a ten-year term and vests over four years, with 25% of the original number of shares vesting on the one-year anniversary of the date of grant, and the remainder vesting in equal monthly installments over the three years after such date, subject to the recipient’s continued service to Ocular through the applicable vesting dates. Each of the restricted stock unit awards vests over three years, in equal annual installments on the first, second and third anniversaries of the date of grant, subject to the recipient’s continued service to Ocular through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of the award agreements covering the grants and Ocular’s 2019 Inducement Stock Incentive Plan.

About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).

Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA^®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.

Follow the Company on its website, LinkedIn, or X.

DEXTENZA^® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.

Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com

VANCOUVER, British Columbia, Sept. 18, 2026 (GLOBE NEWSWIRE) — Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), Canada’s leading premium licensed producer focused on cultivating and selling premium and super-premium cannabis products, is pleased to announce the launch of 1964 Supply Co.™ (“1964”) full spectrum vapes in the United Kingdom through its distribution partnership with 4C LABS.

“The response to 1964 in the U.K. has demonstrated that there is growing demand for premium medical cannabis products in international markets,” said Margaret Brodie, Chief Executive Officer of Rubicon Organics. “With patient numbers in the U.K. expected to grow 40% this year¹, and vape offerings increasingly popular, the launch of 1964 full spectrum vapes builds on the success of the brand in the U.K. and further strengthens our position in a rapidly expanding market.”

1964 first entered the U.K. market with its award-winning Blue Dream and Stinky Pinky flower strains in April. Rubicon Organics has since expanded the brand’s flower offerings to include its Apples and Bananas flower, and the launch of full spectrum vapes marks the next step in developing the 1964 portfolio for the U.K. medical cannabis market. By extending its premium genetics into vape formats, 1964 provides patients with additional consumption options beyond flower while maintaining the quality, consistency, and cultivar-driven experience associated with the brand.

1964 is one of Rubicon Organics’ flagship brands and one of Canada’s leading premium cannabis brands, having won numerous awards including Brand of the Year for the last two years at the industry’s prestigious KIND Awards. The brand is inspired by classic legacy genetics and designed to deliver genuine, high-quality cannabis with a focus on consistency and trust.

ABOUT RUBICON ORGANICS INC.

Rubicon Organics is the Canadian leader in certified organic and premium cannabis. With a vertically integrated model and strong national distribution, the company is scaling a house of trusted, high-performing brands including Simply Bare™ Organic, 1964 Supply Co.™, Wildflower™, and Homestead Cannabis Supply™.

The Company operates two complementary cultivation facilities in British Columbia: the flagship 125,000 square foot Pacifica hybrid greenhouse in Delta and the 47,500 square foot Cascadia indoor facility in Hope. Cascadia is now fully planted and operational, contributing to Rubicon’s total current annual production capacity of approximately 15,500 kilograms of premium cannabis.

With proprietary genetics, award-winning products, and certifications enabling international distribution, Rubicon is positioned at the forefront of the premium cannabis segment.

As the Canadian market continues to evolve and global demand for high-quality cannabis increases, Rubicon Organics’ disciplined execution, brand equity, and consumer loyalty set it apart. The Company’s continued focus on premium quality, thoughtful innovation, and operational excellence has supported steady revenue growth and positive Adjusted EBITDA.

Rubicon Organics represents a rare combination of category leadership, operational strength, and long-term growth potential.

For more information visit www.rubiconorganics.com.

ABOUT 4C LABS

4C LABS Ltd. is a privately held Canadian medical cannabis company focusing on providing pharmacies & clinics with world class medical cannabis products at an affordable price. 4C LABS has import and distribution licenses in the UK and a wide network of pharmacies in the UK & Channel Islands. 4C LABS carries a full product line of medical cannabis from a selected network of trusted international cultivation partners. For more information, please visit www.4clabs.co.

CONTACT INFORMATION

Margaret Brodie
CEO
Phone: +1 (437) 929-1964
Email: ir@rubiconorganics.com

The TSX Venture Exchange or its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) does not accept responsibility for the adequacy or accuracy of this press release.

Cautionary Statement Regarding Forward Looking Information

This press release contains forward-looking information within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance are “forward-looking statements”. Forward-looking information can be identified by the use of words such as “will” or variations of such words or statements that certain actions, events or results “will” be taken, occur or be achieved.

Forward-looking information is based on management’s current expectations, estimates, projections and assumptions as of the date of this press release, including, without limitation, assumptions regarding continued patient demand for premium medical cannabis products; the continued availability of regulatory approvals and import permits; the ability of 4C LABS and other third parties to distribute the Company’s products; stable market conditions; the Company’s ability to maintain product quality, supply and production levels; and the Company’s ability to successfully execute its business and international expansion strategies.

Forward-looking information in this press release includes, without limitation, statements regarding the Company’s international growth strategy; the expansion and development of the 1964 Supply Co.™ portfolio in the United Kingdom; the availability, distribution and commercial performance of the Company’s products in the U.K. medical cannabis market; demand for premium medical cannabis products in international markets; the continuation and success of the Company’s distribution partnership with 4C LABS; the Company’s ability to expand its presence in regulated international markets; the expected benefits of new product launches; and the Company’s production capacity, revenue growth opportunities and strategic initiatives.

Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking information. Such risks and uncertainties include, among others, the risk that anticipated production, yield, operational efficiency, revenue, margin or profitability targets are not achieved; changes in market conditions, consumer demand, and competition; changes in laws, regulations and regulatory policies governing medical cannabis in Canada, the United Kingdom and other international markets; reliance on third-party distributors and service providers; pricing pressures; product recalls; supply chain disruptions; foreign exchange fluctuations; challenges in maintaining required certifications and quality standards; access to capital; and the other risk factors described under the heading “Risk Factors” in Rubicon Organics’ Annual Information Form dated March 23, 2026, filed with the Canadian securities regulatory authorities.

Readers are cautioned not to place undue reliance on forward-looking statements. Although the Company believes that the expectations and assumptions underlying such statements are reasonable, there can be no assurance that they will prove to be accurate, and actual results and future events may differ materially from those anticipated. Except as required by applicable law, Rubicon Organics undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

¹ Prohibition Partners, UK Medical Cannabis Market Update 2026 (June 2026)

McFarlane Lake Mining joins five other companies from Michael Gentile’s portfolio across a five-city program running October 19 through 23, 2026

TORONTO, Sept. 18, 2026 (GLOBE NEWSWIRE) — McFarlane Lake Mining Limited (“McFarlane” or the “Company”) (CSE: MLM, OTC: MLMLF, FRA: W2Z) today announced its participation in the inaugural Gentile Mining Investor Forum, a full-day investor conference in London on Monday, October 19, and the Michael Gentile Mining & Metals European Roadshow, continuing to Paris, Frankfurt, Zurich, and Munich from October 20 through 23. The program is presented by strategic junior mining investor Michael Gentile in partnership with Amvest Capital Inc. and supported by flagship sponsors ATB Cormark Capital Markets, Beacon Securities Limited, and STIFEL. Full program details and registration are available at gentileminingroadshow.com.

“We’re excited to bring the Juby Gold story to European investors,” said Mark Trevisiol, Chief Executive Officer, President and Director of McFarlane. “With the significant resource growth we have demonstrated at Juby and our recently completed financing supporting continued drilling and project advancement, we have strong momentum heading into this program. This is an excellent opportunity to introduce Juby’s scale and potential to a broader global investor audience.”

McFarlane Lake Mining is one of six companies from Gentile’s portfolio participating in the full five-city program. The program opens with the Forum on Monday, October 19 at 116 Pall Mall in Mayfair, London, bringing together up to 150 investors, family offices, wealth managers, and sector-focused high-net-worth individuals for a full day of structured one-on-one meetings and dedicated issuer showcases alongside over 20 companies from Gentile’s portfolio.

The day opens with a keynote breakfast featuring Michael Gentile, presented by session sponsor Canaccord Genuity, followed by issuer showcases presented by TSX and TSX Venture Exchange, an executive lunch and speaker panel, and an all-day investor lounge and networking reception hosted by session sponsor Investor.Events. Crux Investor serves as the Forum’s media sponsor.

The Roadshow then continues to Paris (October 20), Frankfurt (October 21), Zurich (October 22), and Munich (October 23), where McFarlane Lake Mining will take part in structured one-on-one investor meetings and a hosted lunch presentation in each city, including a keynote by Gentile.

“Our team has spent years building relationships with resource investors across North and South America, Europe, and Asia. This program puts that network to work, giving these companies direct access to a global base of qualified investors in a single room,” said Gabriel Alonso-Mendoza, Co-Founder and Managing Partner of Amvest Capital. “Michael’s conviction and hands-on approach to these companies fit perfectly with our firm’s philosophy. We are thrilled to once again partner with Michael and his portfolio companies.”

Investor Registration

Investor registration is now open for events in all five cities. Investor attendance is free of charge; registrations are reviewed prior to confirmation. Space is limited, and meetings are allocated on a first-confirmed basis. Full program details and registration are available at gentileminingroadshow.com.

About McFarlane Lake Mining Limited

McFarlane Lake is a gold exploration company focused on exploring and advancing the Juby Gold project near Gowganda, Ontario. The Juby Gold project has a (NI 43-101) inferred resource of 5.06 million ounces of gold at 0.87 gpt contained in 180.67 million tonnes and Indicated resources of 1.14 million ounces of gold at 0.95 gpt contained in 37.17 million tonnes, using a long-term gold price of US$3,600/oz. These resources have an effective date of August 14, 2026. Sensitivities performed at higher gold prices – US$4,600/oz gold- the deposit holds 5.40 million inferred ounces at 0.85 gpt gold and 1.20 million indicated ounces at 0.93 gpt gold.

The full technical report on these resources will be issued within 45 days of the Company’s MRE announcement. The technical report will be issued by BBA E&C Inc., an independent organization from McFarlane Lake Mining. McFarlane is currently planning to perform exploration drilling on the Juby Gold Project as well as other study work to advance the development of the property.

In addition to the Juby Gold Project, McFarlane holds a portfolio of 100%-owned gold assets across Ontario, including the past-producing McMillan Gold Mine and Mongowin properties located approximately 70 km west of Sudbury and the Michaud/Munro properties located 115 km east of Timmins. McFarlane is a reporting issuer in Ontario, British Columbia, and Alberta.

Readers are cautioned to refer to the “Cautionary Note Regarding Forward-Looking Information” and all other disclaimers included in this news release for important information regarding the limitations and verification status of the data presented above and elsewhere herein.

About Michael Gentile

Michael Gentile is widely recognized as a leading strategic investor in the junior mining sector. He began his investing career in 2002 at Formula Growth Limited, where he spent 17 years, and from 2012 to 2018 co-managed one of Canada’s largest market-neutral hedge funds alongside his partner, Charles Haggar. In 2022 he co-founded Bastion Asset Management, a Montreal-based investment firm that manages more than CAD $900 million in small and mid-cap equities across the United States and Canada. Since 2018 he has applied a disciplined, portfolio-based approach to junior mining, and today holds top shareholder positions in 35 companies in the sector and serves on six boards.

About Amvest Capital

Amvest Capital is a New York-based investment bank and funds management firm focused solely on natural resources. The firm partners with companies and management teams to develop and finance high-quality natural resource assets worldwide, combining disciplined capital allocation with strategic advisory expertise to advance responsible and sustainable resource development. As part of its business, Amvest Capital conducts investor roadshows across North America, Europe, Australia, and beyond for NYSE, TSX, TSX-V, ASX, and LSE-listed clients, with deep relationships across the institutional investor community in global markets. Learn more at amvestcapital.com.

Further Information

For further information regarding McFarlane Lake, please contact:

Bryan Baritot, Investor Relations
McFarlane Lake Mining Limited
investors@mcfarlanelakemining.com

Mark Trevisiol
Chief Executive Officer, President and Director
McFarlane Lake Mining Limited
705 665 5087
mtrevisiol@mcfarlanelakemining.com

To learn more, visit: https://mcfarlanelakemining.com/

Additional information on McFarlane Lake can be found by reviewing its profile on SEDAR+ at www.sedarplus.ca.

Cautionary Statement Regarding Forward-Looking Information

This news release contains certain “forward-looking information” within the meaning of Canadian securities legislation, including, but not limited to, statements regarding the Company’s plans with respect to the Company’s projects and the timing related thereto, the merits of the Company’s projects, the Company’s objectives, plans and strategies, the tax treatment of the FT Shares, the use of proceeds of the Offering, and other matters. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “aims,” “potential,” “goal,” “objective,”, “strategy”, “prospective,” and similar expressions, or that events or conditions “will,” “would,” “may,” “can,” “could” or “should” occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except to the extent required by applicable securities laws and the policies of the CSE, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause future results to differ materially from those anticipated in these forward-looking statements include the risk of accidents and other risks associated with mineral exploration operations, the risk that the Company will encounter unanticipated geological factors, or the possibility that the Company may not be able to secure permitting and other agency or governmental clearances, necessary to carry out the Company’s exploration plans, risks of political uncertainties and regulatory or legal changes in the jurisdictions where the Company carries on its business that might interfere with the Company’s business and prospects. The reader is urged to refer to the Company’s reports, publicly available through the Canadian Securities Administrators’ System for Electronic Data Analysis and Retrieval + (SEDAR+) at www.sedarplus.ca for a more complete discussion of such risk factors and their potential effects.

Cautionary Statement on Mineral Resources

This news release uses the terms indicated and inferred mineral resources as a relative measure of the level of confidence in the resource estimate. Readers are cautioned that mineral resources are not mineral reserves and that the economic viability of resources that are not mineral reserves has not been demonstrated. The mineral resource estimates disclosed in this news release may be materially affected by geology, environmental, permitting, legal, title, socio-political, marketing or other relevant issues. It cannot be assumed that all or any part of an inferred mineral resource will ever be upgraded to an indicated or measured mineral resource category; however, it is reasonably expected that the majority of Inferred Mineral Resources could be upgraded to Indicated Mineral Resources with continued exploration. The mineral resource estimate is classified in accordance with the Canadian Institute of Mining, Metallurgy and Petroleum’s “CIM Definition Standards on Mineral Resources and Mineral Reserves” incorporated by reference into NI 43-101. Under NI 43-101, estimates of inferred mineral resources may not form the basis of feasibility or pre-feasibility studies or economic studies except for preliminary economic assessments. Readers are cautioned not to assume that further work on the stated resources will lead to mineral reserves that can be mined economically.

Qualified Person

Mark Trevisiol, P.Eng. (ON), President and CEO of McFarlane Lake Mining and a non-independent Qualified Person as defined by National Instrument 43-101, has approved and verified the technical information used in this news release. The mineral resource estimate referenced herein was prepared by BBA E&C Inc., an independent organization from McFarlane Lake Mining.

Strengthened balance sheet with successful completion of upsized $168.3 million initial public offering

Announced FDA Fast Track designation for BH-30643 for the treatment of advanced
EGFR C797S-positive NSCLC

SAN DIEGO, Sept. 18, 2026 (GLOBE NEWSWIRE) — BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced financial results for the second quarter 2026 and highlighted recent progress.

“We’ve achieved meaningful progress across our pipeline, as well as our significant corporate milestones, since the beginning of the second quarter,” said Jean Cui, Ph.D., Founder, President and Chief Executive Officer of BlossomHill Therapeutics. “In April, we presented our first preclinical data from our pseudo-irreversible pan-KRAS inhibitor BH-501284, built on a novel chemical scaffold, at AACR where we highlighted the sustained target engagement leading to tumor regression at low dose levels. At ASCO in early June we presented the preliminary safety, PK and antitumor activities of BH-30643 in Phase 1 dose escalation of the SOLARA trial, along with the initial efficacy data in C797S-positive NSCLC. More recently we announced that BH-30643 received Fast Track designation, an important regulatory milestone that reflects the FDA’s recognition of the potential for this molecule. We also presented encouraging safety data and early signs of anti-leukemic activity observed with BH-30236, our novel macrocyclic CLK inhibitor, both as a monotherapy and in combination with venetoclax, at EHA in the middle of June. We are now looking forward to our end-of-phase 1 meeting with the FDA later this year. With a strong balance sheet following our successful initial public offering in August, we believe we are well positioned to deliver important clinical and regulatory milestones over the coming quarters as we continue advancing our intentionally designed medicines that address significant unmet medical needs in cancer treatment.”

Recent Business Highlights and Corporate Updates:

• Strengthened the balance sheet with approximately $168.3 million in gross proceeds from the initial public offering (IPO) in August 2026
• Announced the U.S. Food and Drug Administration (FDA) granted Fast Track designation to BH-30643, a macrocyclic OMNI-EGFR™ inhibitor, for the treatment of adult patients with advanced or metastatic epidermal growth factor receptor (EGFR) C797S-positive non-small cell lung cancer (NSCLC) after prior treatment with a third-generation EGFR tyrosine kinase inhibitor (TKI)
• Presented preliminary results of BH-30643 from dose escalation and backfill cohorts in the ongoing Phase 1/2 SOLARA trial in advanced or metastatic EGFR-mutant NSCLC at the American Society of Clinical Oncology (ASCO) 2026 annual meeting, and additional follow up data at IASLC 2026 World Conference on Lung Cancer, which highlighted a 45% objective response rate and 88% disease control rate observed in patients with C797S resistance to prior TKIs, with or without concurrent T790M mutation
• Presented the first preclinical data from the pseudo-irreversible pan-KRAS inhibitor BH-501284, built on a novel chemical scaffold, at the American Association for Cancer Research (AACR) 2026 annual meeting
• Presented initial clinical data from the ongoing first-in-human Phase 1/1b trial of BH-30236, an orally bioavailable, macrocyclic CDC-like kinase (CLK) inhibitor, in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS) at the European Hematology Association (EHA) 2026 Congress
• Expanded the Company’s Board of Directors with the appointments of Sheila Gujrathi, M.D., and John Schmid

Anticipated Upcoming Milestones:
BH-30643

• Q4 2026: End of Phase 1 meeting regarding a recommended Phase 2 dose selection and a potential accelerated approval pathway in C797S resistance
• Q1 2027: First patient dosed in anticipated pivotal Phase 2 trial
• 1H 2027: Updated Phase 1 data, including C797S durability
• 2H 2027: Updated Phase 1 data on TKI-naive durability and initial chemo combo cohort data

BH-501284

• Q1 2027: Investigational New Drug submission

BH-30236  

• 1H 2027: Updated Phase 1 data on safety and anti-leukemic effect

Second Quarter 2026 Financial Results

Research and development (R&D) expenses for the second quarter of 2026 were $21.4 million, compared with $12.5 million for the same period in 2025. The increase was primarily due to greater clinical development expenses driven by the SOLARA trial, expenses to support IND-enabling studies for BH-501284, and greater costs related to personnel, facilities and other overhead.

General and administrative (G&A) expenses for the second quarter of 2026 were $3.3 million, compared with $1.6 million for the same period in 2025. The increase was primarily due to greater legal expenses, personnel-related expenses and overhead.

Net loss for the second quarter of 2026 was $23.8 million, or $(8.75) per basic and diluted share, compared with a net loss of $13.2 million, or $(5.51) per basic and diluted share for the same period in 2025. The increase in net loss was primarily attributable to increased operating expenses.

Cash and cash equivalents totaled $95.4 million as of June 30, 2026. BlossomHill subsequently completed its IPO in August 2026 in which it sold 10,516,240 shares of its common stock, including partial exercise of the over-allotment option, for gross proceeds of $168.3 million. BlossomHill believes that its cash and cash equivalents as of June 30, 2026, together with the proceeds from its IPO, will be sufficient to fund its operations into the second quarter of 2028.

About BH-30643
BH-30643 is an investigational, novel, orally bioavailable, non-covalent, macrocyclic, brain active, mutant-selective, OMNI-EGFR™ inhibitor for the treatment of EGFR-mutant NSCLC. BH-30643 was designed to overcome the limitations of currently approved EGFR inhibitors, which were discovered over a decade ago without the current, modern understanding of the structure and protein dynamics of mutant EGFRs. In preclinical studies, BH-30643 demonstrated potent inhibitory activity across diverse EGFR mutation categories – classical mutations, on-target resistance mutations such as C797S with or without T790M, atypical mutations and exon 20 insertions – while maintaining marked selectivity over wild-type EGFR. BH-30643 has received Fast Track designation and is being evaluated in SOLARA, a global Phase 1/2, first-in-human clinical trial spanning more than 40 sites in 10 countries. Ongoing dose expansion cohorts are enrolling in both TKI-pretreated and TKI-naive settings, including a C797S resistance cohort. For additional information on SOLARA, including a list of study sites and how to enroll, please visit clinicaltrials.gov (NCT06706076).

About BH-30236
BH-30236 is an investigational orally bioavailable, macrocyclic inhibitor of the CDC-like kinase (CLK) family. BH-30236 was intentionally designed to potently inhibit CLK, leading to modulation of aberrant alternative splicing in cancerous tissue, targeting the same aberrant splicing machinery that drives relapsed or refractory (R/R) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) disease biology and that cancer cells exploit to develop resistance to venetoclax, FLT3 inhibitors and cytarabine.   BH-30236 is being evaluated in a Phase 1/1b multicenter, open-label, first-in-human dose escalation and expansion trial in adults with R/R AML and HR-MDS. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BH-30236 for the treatment of AML. For additional information on this trial, including a list of study sites and how to enroll, please visit clinicaltrials.gov (NCT06501196).

About BH-501284
BH-501284 is an investigational, orally bioavailable pan-KRAS inhibitor, which utilizes a novel Switch-II chemical scaffold to achieve prolonged, potent and selective inhibition of KRAS mutations. We believe this molecule, which uses a non-covalent scaffold, is unique in its potential to achieve tight and durable binding, a feature described as “pseudo-irreversible” binding. In preclinical studies, BH-501284 has achieved pseudo-irreversible binding characteristics with high binding affinity, while maintaining high selectivity for KRAS.

About BlossomHill Therapeutics
BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development – including three FDA-approved drugs – BlossomHill Therapeutics applies cutting-edge science with a goal to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers. The company’s lead clinical program is BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR^TM inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), which has received Fast Track designation for the C797S resistance population after 3rd generation EGFR TKI treatment. The company is also conducting clinical development of BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor initially being studied in a clinical trial for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS). The company’s pipeline also includes BH-501284, a preclinical, non-covalent, selective, pan-KRAS Switch-II inhibitor for potential future development in diverse KRAS-mutant tumors.

BlossomHill Therapeutics is headquartered in San Diego, California. For more information, visit bhtherapeutics.com and follow us on LinkedIn and X.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and other federal securities laws, including, without limitation, statements regarding: the therapeutic potential, clinical benefits, safety and potential competitive differentiation of the company’s product candidates, including BH-30643, BH-30236 and BH-501284; the anticipated benefits of regulatory designations received, or that may be received, by the company’s product candidates; the design, enrollment, timing, progress and results of the company’s clinical trials and preclinical studies; the company’s planned regulatory interactions and submissions; anticipated program milestones, including the timing of program and data updates; the period over which the company estimates its existing cash and cash equivalents, together with the net proceeds from its initial public offering, will be sufficient to fund its current operating plan; statements by the company’s management; and the company’s development plans and continued advancement of its pipeline. The words “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “upcoming,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially, including, without limitation: the company’s limited operating history, history of significant losses and the early stage of development of its product candidates; the risk that preliminary and interim clinical data are subject to further analysis and may not be predictive of, may be inconsistent with, or may be more favorable than, data generated as clinical trials continue or data from future clinical trials; uncertainties inherent in the initiation, timing, design and enrollment of clinical trials, and the availability and timing of data from ongoing and future trials; the company’s ability to successfully demonstrate the safety and efficacy of its product candidates and to obtain and maintain regulatory approvals; the timing and outcome of planned interactions with, and submissions to, the FDA and other regulatory authorities, including whether an accelerated approval pathway will be available to the company; the risk that regulatory designations, including Fast Track and orphan drug designation, may not result in a faster development, review or approval process, may not increase the likelihood of regulatory approval, and may be withdrawn; competition from third parties that are developing products for similar indications; the prior success of the company’s management team may not be indicative of future success; the company’s reliance on third parties, including contract research organizations and contract manufacturing organizations; the company’s ability to obtain, maintain and protect its intellectual property; and the company’s need for additional financing and its estimates regarding operating expenses and capital requirements. These and other risks are described in greater detail under the heading “Risk Factors” in the company’s filings with the Securities and Exchange Commission (the “SEC”), its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which will be filed with the SEC later today, as well as in the company’s subsequent filings with the SEC. Any forward-looking statements represent the company’s views only as of the date of this press release, and the company expressly disclaims any obligation to update any forward-looking statements, except as required by law.

Company Contact:
Michael Moore, BlossomHill Therapeutics
michael.moore@bhtherapeutics.com

Media:
Ashlea Kosikowski, 1AB
ashlea@1abmedia.com

BLOSSOMHILL THERAPEUTICS, INC. UNAUDITED CONDENSED BALANCE SHEETS (in thousands, except share and par value data)
			June 30, 2026							December 31, 2025
			(unaudited)
Assets
Current Assets:
Cash and cash equivalents				$	95,376						$	136,682
Prepaid expenses and other current assets					5,592							2,144
Total current assets					100,968							138,826
Property and equipment, net					1,489							1,726
Operating lease right-of-use assets					19,197							19,921
Other assets					2,477							2,495
Total assets				$	124,131						$	162,968
Liabilities, convertible preferred stock and stockholders’ deficit
Current liabilities:
Accounts payable				$	3,930						$	2,314
Accrued expenses					9,194							8,431
Accrued compensation					3,539							4,730
Other current liabilities					809							–
Operating lease liability, current					1,149							5
Total current liabilities					18,621							15,480
Operating lease liability, non-current					22,222							22,393
Other long-term liabilities					1,245							–
Total liabilities					42,088							37,873
Convertible preferred stock, $0.0001 par value; 85,552,612 shares authorized at June 30, 2026 and December 31, 2025; 18,258,960 shares issued and outstanding at June 30, 2026 and December 31, 2025; $257,153 aggregate liquidation preference at June 30, 2026 and December 31, 2025					256,823							256,823
Stockholders’ deficit:
Common stock, $0.0001 par value; 110,000,000 shares authorized at June 30, 2026 and December 31, 2025; 2,767,848 and 2,548,659 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively					1							1
Additional paid-in capital					5,014							3,300
Accumulated deficit					(179,795)							(135,029)
Total stockholders’ deficit					(174,780)							(131,728)
Total liabilities, convertible preferred stock and stockholders’ deficit				$	124,131						$	162,968

BLOSSOMHILL THERAPEUTICS, INC. UNAUDITED CONDENSED STATEMENTS OF OPERATIONS (in thousands, except share and per share data)
		Three Months Ended June 30,								Six Months Ended June 30,
		2026				2025				2026				2025
Operating expenses:
Research and development		$	21,355			$	12,530			$	41,256			$	22,102
General and administrative			3,315				1,573				5,521				3,455
Total operating expenses			24,670				14,103				46,777				25,557
Loss from operations			(24,670	)			(14,103	)			(46,777	)			(25,557	)
Other income (expense), net:
Interest income, net			915				859				2,017				1,835
Other expense, net			(3	)			–				(6	)			–
Total other income, net			912				859				2,011				1,835
Net loss		$	(23,758	)		$	(13,244	)		$	(44,766	)		$	(23,722	)
Net loss per share, basic and diluted		$	(8.75	)		$	(5.51	)		$	(16.91	)		$	(9.90	)
Weighted average common shares outstanding, basic and diluted			2,713,696				2,405,140				2,646,721				2,395,789

Cambria Gold Mines Inc. joins over 20 companies from Michael Gentile’s portfolio at the inaugural Forum on October 19, 2026, in Mayfair, London

VANCOUVER, British Columbia, Sept. 18, 2026 (GLOBE NEWSWIRE) — Cambria Gold Mines Inc. (TSXV: CAMB; OTCQX: CAMVF) today announced its participation in the inaugural Gentile Mining Investor Forum, a full-day investor conference in London on Monday, October 19, 2026, at 116 Pall Mall in Mayfair. The program is presented by strategic junior mining investor Michael Gentile in partnership with Amvest Capital Inc. (“Amvest Capital”), and made possible by the generous support of Flagship Sponsors ATB Cormark Capital Markets, Beacon Securities Limited, and STIFEL. Full program details and registration are available at gentileminingroadshow.com.

“I created this program to give serious investors direct, in-person access to a select group of companies I’ve backed with conviction. Each one represents what I believe to be a high-potential opportunity in the mining sector. These are names I have researched deeply, invested in personally, and believe have the potential to deliver meaningful value. Amvest Capital has been an outstanding partner in building a week of events that meets the standards these investors and companies deserve,” said Michael Gentile.

The Forum will bring together up to 150 investors, family offices, wealth managers, and sector-focused high-net-worth individuals for a full day of structured one-on-one meetings and dedicated issuer showcases alongside over 20 companies from Gentile’s portfolio, including Cambria Gold Mines Inc. The day opens with a keynote breakfast featuring Michael Gentile, presented by session sponsor Canaccord Genuity, followed by issuer showcases presented by TSX and TSX Venture Exchange, an executive lunch and speaker panel, and an all-day investor lounge and networking reception hosted by session sponsor Investor. Events. Crux Investor serves as the Forum’s media sponsor.

“Our team has spent years building relationships with resource investors across North and South America, Europe, and Asia. This program puts that network to work, giving these companies direct access to a global base of qualified investors in a single room,” said Gabriel Alonso-Mendoza, Co-Founder and Managing Partner of Amvest Capital. “Michael’s conviction and hands-on approach to these companies fit perfectly with our firm’s philosophy. We are thrilled to once again partner with Michael and his portfolio companies.”

Register Now

Investor registration is now open. Investor attendance is free of charge; registrations are reviewed prior to confirmation. Space is limited, and meetings are allocated on a first-confirmed basis. Full program details and registration are available at gentileminingroadshow.com.

About Cambria Gold Mines Inc.

Cambria is advancing a focused redevelopment of a legacy gold mining complex in British Columbia’s Golden Triangle. By aligning high-grade geology, existing infrastructure, and experienced leadership, Cambria is positioned to move methodically toward sustainable, long-life production.

This is an execution-driven opportunity built on what already exists — permitted assets, substantial investment, and a clear development pathway — guided by a team with direct experience restarting complex mining operations.

About Michael Gentile

Michael Gentile is widely recognized as a leading strategic investor in the junior mining sector. He began his investing career in 2002 at Formula Growth Limited, where he spent 17 years, and from 2012 to 2018 co-managed one of Canada’s largest market-neutral hedge funds alongside his partner, Charles Haggar. In 2022 he co-founded Bastion Asset Management, a Montreal-based investment firm that manages more than CAD $900 million in small and mid-cap equities across the United States and Canada. Since 2018 he has applied a disciplined, portfolio-based approach to junior mining, and today holds top shareholder positions in 35 companies in the sector and serves on six boards.

About Amvest Capital

Amvest Capital is a New York-based investment bank and funds management firm focused solely on natural resources. The firm partners with companies and management teams to develop and finance high-quality natural resource assets worldwide, combining disciplined capital allocation with strategic advisory expertise to advance responsible and sustainable resource development. As part of its business, Amvest Capital conducts investor roadshows across North America, Europe, Australia, and beyond for NYSE, TSX, TSX-V, ASX, and LSE-listed clients, with deep relationships across the institutional investor community in global markets. Learn more at amvestcapital.com.

For more information, please contact:

Sam Brezden
Email: sam.brezden@cambriagold.com
Phone: 236-838-1840

Cautionary Statements:

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Cautionary Statement Regarding Forward-Looking Information

All statements and other information contained in this press release about anticipated future events may constitute forward-looking information under Canadian securities laws (“forward-looking statements”). Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeted”, “outlook”, “on track” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, “would” or “might” occur or be achieved and other similar expressions. All statements, other than statements of historical fact, included herein are forward-looking statements, including the timing, positioning and completion of the construction on the access road; the future commencement of trucking of production at the Premier Mine; the timing and successful completion of an updated Feasibility Study incorporating all four deposits by Q4 2026; the timing and completion of the fisheries offset work; the ability of the Company to accomplish its business objectives and the intentions described herein; and future plans, development and operations of the Company. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements, risks relating to negative operating cash flows of the Company; business and economic conditions in the mining industry generally; fluctuations in commodity prices and currency exchange rates; environmental compliance; risks related to outstanding debt; uncertainty of estimates and projections relating to development, production, costs and expenses, and health, safety and environmental risks; uncertainties relating to interpretation of drill results and the geology, continuity and grade of mineral deposits; the need to obtain additional financing to finance operations and uncertainty as to the availability and terms of future financing; social media and reputation; negative publicity; human rights; business objectives; shortage of personnel; health and safety; the possibility of delay in future plans and uncertainty of meeting anticipated program milestones; claims and legal proceedings; information systems and cyber security; internal controls; violation of anti-bribery or corruption laws; competition; tax considerations; compliance with listing standards; enforcement of civil liabilities; financing requirement risks; market price volatility of the common shares; uncertainty as to timely availability of permits and other governmental approvals; the need for exchange approval, and other regulatory approvals and other risk factors as detailed from time to time in Cambria’s filings with Canadian securities regulators, available on Cambria’s profile on SEDAR+ at www.sedarplus.ca. Forward-looking statements are based on assumptions made with regard to: the estimated costs associated with the care and maintenance plans; the tax rate applicable to the Company; future commodity prices; the grade of mineral resources and mineral reserves; labor and materials costs increasing on a basis consistent with the Company’s current expectations, the ability of the Company to convert inferred mineral resources to other categories; the ability of the Company to reduce mining dilution; the ability to reduce capital costs; the ability of the Company to raise additional financing; currency exchange rates being approximately consistent with current levels, compliance with the covenants in Cambria’s credit agreements; exploration plans; and general marketing, political, business and economic conditions. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. Although Cambria believes that the expectations reflected in such forward-looking statements and/or information are reasonable, undue reliance should not be placed on forward-looking statements since Cambria can give no assurance that such expectations will prove to be correct. Cambria does not undertake any obligation to update forward-looking statements, other than as required by applicable laws. The forward-looking information contained in this press release is expressly qualified by this cautionary statement.

Leviathan Metals joins over 20 companies from Michael Gentile’s portfolio at the inaugural Forum on October 19, 2026, in Mayfair, London

VANCOUVER, British Columbia, Sept. 18, 2026 (GLOBE NEWSWIRE) — Leviathan Metals Corp. (“Leviathan”, the “Company”) (LVX – TSXV, LVXFF – OTC, 0GP – FSE) today announced its participation in the inaugural Gentile Mining Investor Forum, a full-day investor conference in London on Monday, October 19, 2026, at 116 Pall Mall in Mayfair. The program is presented by strategic junior mining investor Michael Gentile in partnership with Amvest Capital Inc. (“Amvest Capital”), and made possible by the generous support of Flagship Sponsors ATB Cormark Capital Markets, Beacon Securities Limited, and STIFEL. Full program details and registration are available at gentileminingroadshow.com.

“I created this program to give serious investors direct, in-person access to a select group of companies I’ve backed with conviction. Each one represents what I believe to be a high-potential opportunity in the mining sector. These are names I have researched deeply, invested in personally, and believe have the potential to deliver meaningful value. Amvest Capital has been an outstanding partner in building a week of events that meets the standards these investors and companies deserve,” said Michael Gentile.

The Forum will bring together up to 150 investors, family offices, wealth managers, and sector-focused high-net-worth individuals for a full day of structured one-on-one meetings and dedicated issuer showcases alongside over 20 companies from Gentile’s portfolio, including Leviathan Metals Corp. The day opens with a keynote breakfast featuring Michael Gentile, presented by session sponsor Canaccord Genuity, followed by issuer showcases presented by TSX and TSX Venture Exchange, an executive lunch and speaker panel, and an all-day investor lounge and networking reception hosted by session sponsor Investor.Events. Crux Investor serves as the Forum’s media sponsor.

“Our team has spent years building relationships with resource investors across North and South America, Europe, and Asia. This program puts that network to work, giving these companies direct access to a global base of qualified investors in a single room,” said Gabriel Alonso-Mendoza, Co-Founder and Managing Partner of Amvest Capital. “Michael’s conviction and hands-on approach to these companies fit perfectly with our firm’s philosophy. We are thrilled to once again partner with Michael and his portfolio companies.”

Register Now

Investor registration is now open. Investor attendance is free of charge; registrations are reviewed prior to confirmation. Space is limited, and meetings are allocated on a first-confirmed basis. Full program details and registration are available at gentileminingroadshow.com.

About Leviathan Metals Corp.

Leviathan Metals Corp., is a Canadian-based mineral exploration company listed on the TSXV (LVX), Germany (0GP) and OTC (LVXFF). Our flagship property is the Central Project within Botswana’s world-class Kalahari Copper Belt (the ‘KCB’), over which we enjoy 100% ownership, and at which drilling is under way. The Central Project immediately adjoins MMG’s world-class Khoemacau copper-silver cluster, a district-scale system that MMG acquired for approximately US$1.9 billion. This portfolio is complemented by the Serule uranium property, also in Botswana and adjacent to Lotus Resources’ Letlhakane project, as well at the Foča silver-lead-zinc project in Bosnia and Herzegovina, where historic drilling and recent trenching each returned high-grade mineralization. With a strong treasury, active drilling in Botswana, and a strategic prospective land position in one of the world’s most prospective emerging copper belts, Leviathan is positioned for success.

Botswana is a politically stable pro-mining investment jurisdiction – ranked #2 in Africa by the Fraser Institute (2024), enjoying investor-friendly legislation, a highly proficient and well-educated workforce, and first world infrastructure – set up to support mining, which is a pivotal and widely-accepted national economic driver.

About Michael Gentile

Michael Gentile is widely recognized as a leading strategic investor in the junior mining sector. He began his investing career in 2002 at Formula Growth Limited, where he spent 17 years, and from 2012 to 2018 co-managed one of Canada’s largest market-neutral hedge funds alongside his partner, Charles Haggar. In 2022 he co-founded Bastion Asset Management, a Montreal-based investment firm that manages more than CAD $900 million in small and mid-cap equities across the United States and Canada. Since 2018 he has applied a disciplined, portfolio-based approach to junior mining, and today holds top shareholder positions in 35 companies in the sector and serves on six boards.

About Amvest Capital

Amvest Capital is a New York-based investment bank and funds management firm focused solely on natural resources. The firm partners with companies and management teams to develop and finance high-quality natural resource assets worldwide, combining disciplined capital allocation with strategic advisory expertise to advance responsible and sustainable resource development. As part of its business, Amvest Capital conducts investor roadshows across North America, Europe, Australia, and beyond for NYSE, TSX, TSX-V, ASX, and LSE-listed clients, with deep relationships across the institutional investor community in global markets. Learn more at amvestcapital.com.

For more information, please contact:

Luke Norman, Chief Executive Officer and Director
Toll Free: 1-888-875-8832
Email: info@leviathanmetals.com

For further information, please visit the Company website www.leviathanmetals.com and the Company’s profile on SEDAR+ at www.sedarplus.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No securities regulatory authority has either approval or disapproved of the contents of this press release.